Evaluating New Bone and Mineral Metabolism Biomarkers as Cardiovascular Risk Factors in Adults with Chronic Kidney Disease Not on Dialysis

What this Trial Is About

Researchers are studying the links between certain markers of bone mineral metabolism, specifically osteoprotegerin and fibroblast growth factor 23, and the occurrence of cardiovascular events in patients with chronic kidney disease who are not on dialysis. The study aims to understand how these markers relate to heart and blood vessel problems over a long period. Participants will have their blood tested to measure plasma levels of osteoprotegerin and fibroblast growth factor 23, and their vascular calcification will be assessed through imaging scans. These measurements are taken at the start of the study, followed by monitoring for cardiovascular events and kidney function over a 7-year period. During the study, participants will be monitored for the occurrence of cardiovascular events, changes in kidney function, and mortality. The main focus is to see if initial levels of these bone metabolism markers predict cardiovascular problems during the 7 years of follow-up. The study does not involve treatment but evaluates risk factors and outcomes over time.

New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients